- Home
- SRG vs CCCC Comparison
SRG vs CCCC Comparison
Compare SRG & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | CCCC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.7M | 185.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRG | CCCC |
|---|---|---|
| Price | $2.83 | $2.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 199.9K | ★ 2.6M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $2.43 | $1.09 |
| 52 Week High | $4.56 | $3.82 |
Technical Indicators
Market Signals| Indicator | SRG | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.06 | 57.94 |
| Support Level | $2.69 | $2.14 |
| Resistance Level | $3.68 | N/A |
| Average True Range (ATR) | 0.07 | 0.34 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 26.58 | 50.72 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.